Overactivation of the mitogen-activated protein kinase (MAPK) pathway is an important driver of many human cancers. First line, FDA-approved therapies targeting MAPK signalling, which include BRAF and MEK inhibitors, have variable success across cancers, and a significant number of patients quickly develop resistance. In recent years, a number of preclinical studies have reported alternative methods of overcoming resistance, which include promoting apoptosis, modulating autophagy, and targeting mitochondrial metabolism. This review summarizes mechanisms of resistance to approved MAPK-targeted therapies in BRAF-mutated cancers and discusses novel preclinical approaches to overcoming resistance.
There is increasing evidence that oxidative metabolism and fatty acids play an important role in BRAF-driven tumorigenesis, yet the effect of BRAF mutation and expression on metabolism is poorly understood. We examined how BRAF mutation and expression modulates metabolite abundance. Using the non-transformed NIH3T3 cell line, we generated cells that stably overexpressed BRAF V600E or BRAF WT. We found that cells expressing BRAF V600E were enriched with immunomodulatory lipids. Further, we found a unique transcriptional signature that was exclusive to BRAF V600E expression. We also report that BRAF V600E mutation promoted accumulation of long chain polyunsaturated fatty acids (PUFAs) and rewired metabolic flux for non-Warburg behavior. This cancer promoting mutation further induced the formation of tunneling nanotube (TNT)-like protrusions in NIH3T3 cells that preferentially accumulated lipid droplets. In the plasma of melanoma patients harboring the BRAF V600E mutation, levels of lysophosphatidic acid, sphingomyelin, and long chain fatty acids were significantly increased in the cohort of patients that did not respond to BRAF inhibitor therapy. Our findings show BRAF V600 status plays an important role in regulating immunomodulatory lipid profiles and lipid trafficking, which may inform future therapy across cancers.
5 May 2025 in JNCI: Journal of the National Cancer Institute
Background: Patient-reported outcomes are critical for assessing symptomatic adverse events in non–small-cell lung cancer (NSCLC) clinical trials, but these reports may not fully capture tyrosine kinase inhibitor–specific adverse events in patients with metastatic NSCLC. This study evaluated coverage of tyrosine kinase inhibitor–related symptomatic adverse events by commonly used patient-reported outcomes item libraries. Methods: We compiled a list of US Food and Drug Administration–approved tyrosine kinase inhibitors for NSCLC with alterations in EGFR, ALK, ROS1, RET, MET, and NTRK. Symptomatic adverse events were extracted from clinical trials reported in US prescribing information (ie, drug labels). The European Organisation for Research and Treatment of Cancer (EORTC), Patient-Reported Outcomes Measurement Information System (PROMIS), and Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item libraries were searched for items corresponding to extracted adverse events. Items were classified according to the adverse event’s physical, functional, and social or emotional impact. Results: Data from 17 drug labels covering 29 clinical trials of 17 tyrosine kinase inhibitors were analyzed. By tyrosine kinase inhibitor, EORTC covered the highest average percentage of adverse events (99%), followed by PRO-CTCAE (86%) and PROMIS (47%). Of the 15 most common adverse events, 8 were covered by all 3 item libraries. The EORTC and PRO-CTCAE covered 15 adverse events, whereas PROMIS covered 8. Of the 8 adverse events covered by all 3 libraries, PROMIS included the most items assessing functional and social or emotional impact. Conclusions: The EORTC and PRO-CTCAE covered more symptomatic adverse events than PROMIS. For the adverse events it covered, PROMIS had the most items assessing functional and social or emotional impact. Our assessment is a starting point for improving patient-reported outcome coverage of adverse events associated with new treatments such as tyrosine kinase inhibitors.
Acquired factor X (FX) deficiency is a rare but well-documented clinical feature of AL amyloidosis. Patients with FX deficiency can present with clinically significant bleeding diathesis due to the adsorption of circulating FX to amyloid fibrils. Here, we report an unusual case of a man in his 60s who presented with 6 months of intermittent bruising, labs demonstrating new FX deficiency, elevated free lambda light chains for underlying AL amyloidosis and concurrent new peroneal vein thrombosis. This is the first report of concurrent thrombotic complications in the setting of AL-amyloid-induced FX deficiency. We discuss the diagnostic and therapeutic conundrum of diagnosing AL amyloidosis with bruising as the leading clinical symptom and the management of acute deep vein thrombosis in the setting of FX deficiency.